| name | endo-withhold-medical-therapy-pregnancy-except-tumor-headache |
| description | Recommends that medical therapy for acromegaly be withheld during pregnancy and administered only for tumor control and headache relief. Consider when managing a pregnant patient with acromegaly who presents with tumor growth or worsening headache. |
Withhold acromegaly medical therapy during pregnancy except for tumor and headache control
STEP 1 — Gather Information
Confirm pregnancy status (gestational age, symptoms). Review current acromegaly therapy (long-acting SRL, pegvisomant, cabergoline). Assess for headache frequency/severity and tumor-related symptoms (visual changes, bitemporal hemianopsia, new neurologic deficits). Perform or review recent visual field testing and pituitary MRI if available. Document baseline IGF-1 and GH only if clinically indicated for non‑pregnancy-related concerns (otherwise avoid routine pregnancy monitoring).
STEP 2 — Rule In / Rule Out
Is there evidence of tumor growth (progressive visual field defect, new neurologic symptoms, or radiographic progression) or uncontrolled headache requiring intervention?
- Yes → Proceed to STEP 3.
- No → Withhold all long‑acting acromegaly medical therapy (SRL depot, pegvisomant, long‑acting cabergoline) and continue routine obstetric care.
STEP 3 — Classify or Stratify
Classify headache as mild (intermittent, responsive to acetaminophen) or moderate‑severe (daily, disabling). Assess tumor status as stable (no change in visual fields/MRI) or progressive (worsening visual fields, radiographic growth).
- If headache moderate‑severe or tumor progressive → Plan short‑acting octreotide for symptom control.
- If headache mild and tumor stable → Continue withholding therapy; use symptomatic measures only.
STEP 4 — Decide
Withhold long‑acting SRLs (lanreotide autogel/depot, octreotide LAR) and pegvisomant throughout pregnancy. For tumor control or headache relief, administer short‑acting octreotide (50‑100 µg SC) every 6‑8 hours as needed, titrating to symptom relief. Discontinue short‑acting octreotide once symptoms resolve. Schedule visual field testing every trimester and clinical assessment monthly; resume pre‑pregnancy medical therapy postpartum after lactation cessation if desired.
Clinical Guardrails / Mimics / Pitfalls
Do not initiate or continue long‑acting SRLs, pegvisomant, or long‑acting cabergoline during pregnancy due to limited fetal safety data. Avoid routine GH/IGF‑1 monitoring in pregnancy as placental GH confounds assays. Do not assume cabergoline is safe without obstetric consultation; use only if prolactinoma co‑exists and under specialist guidance. Monitor for gestational diabetes and hypertension, which are modestly increased in acromegaly. Never withhold therapy for acute visual field deterioration; treat promptly with short‑acting octreotide and neurosurgical evaluation.
Concrete Clinical Example
A 28‑year‑on woman with acromegaly on lanreotide autogel 120 mg monthly presents at 14 weeks gestation with worsening frontotemporal headache; visual fields are stable and MRI shows no tumor change. Discontinue lanreotide, treat headache with short‑acting octreotide 50 µg SC q6‑8 h PRN, and reassess headache daily. Headache resolves by week 16; octreotide is tapered off. Continue obstetric follow‑up and plan to restart lanreotide postpartum.
Source: Acromegaly: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, DOI:10.1210/jc.2014-2700
